Article Information
History
- February 3, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Prof Francisco J. de Abajo, MD, PhD, MPH1,2,†,
- Antonio Rodríguez-Miguel, PhD1,2,
- Sara Rodríguez-Martín, PhD1,2,
- Victoria Lerma, RN1,
- Alberto García-Lledó, MD, PhD3,4 and
- on behalf of MED-ACE2-COVID19 Study Group*
- 1Clinical Pharmacology Unit. University Hospital Príncipe de Asturias. Alcalá de Henares. Madrid. Spain
- 2Department of Biomedical Sciences (Pharmacology Section). University of Alcalá (IRYCIS). Alcalá de Henares. Madrid. Spain
- 3Department of Cardiology, University Hospital Príncipe de Asturias. Alcalá de Henares. Madrid. Spain
- 4Department of Medicine, University of Alcalá (IRYCIS). Alcalá de Henares. Madrid. Spain
- ↵†Author for correspondence:
Prof. Francisco J. de Abajo, Clinical Pharmacology Unit, University Hospital Principe de Asturias, Department of Biomedical Sciences, University of Alcalá (IRYCIS), Tel. 91887 81 00 (ext 2607) - 91 885 25 93, e-mail: francisco.abajo{at}uah.es
Posted February 03, 2021.
IN-HOSPITAL CONTINUATION WITH ANGIOTENSIN RECEPTOR BLOCKERS IS ASSOCIATED WITH A LOWER MORTALITY RATE THAN CONTINUATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN COVID-19 PATIENTS: A RETROSPECTIVE COHORT STUDY
